Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2007 2
2008 1
2009 1
2010 7
2011 9
2012 11
2013 5
2014 10
2015 7
2016 7
2017 13
2018 5
2019 6
2020 2
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28844815

81 results

Results by year

Filters applied: . Clear all
Page 1
Pazopanib for advanced liposarcoma.
Gilbert JA. Gilbert JA. Lancet Oncol. 2017 Oct;18(10):e564. doi: 10.1016/S1470-2045(17)30663-0. Epub 2017 Aug 24. Lancet Oncol. 2017. PMID: 28844815 No abstract available.
Kinase inhibitors for refractory thyroid cancers.
Schlumberger M. Schlumberger M. Lancet Oncol. 2010 Oct;11(10):912-3. doi: 10.1016/S1470-2045(10)70226-6. Epub 2010 Sep 17. Lancet Oncol. 2010. PMID: 20851683 No abstract available.
Pazopanib.
Bukowski RM, Yasothan U, Kirkpatrick P. Bukowski RM, et al. Nat Rev Drug Discov. 2010 Jan;9(1):17-8. doi: 10.1038/nrd3073. Nat Rev Drug Discov. 2010. PMID: 20043026
Pazopanib for the treatment of renal cancer.
Al-Marrawi MY, Rini B. Al-Marrawi MY, et al. Expert Opin Pharmacother. 2011 May;12(7):1171-89. doi: 10.1517/14656566.2011.571206. Epub 2011 Apr 7. Expert Opin Pharmacother. 2011. PMID: 21470066 Review.
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium. Bible KC, et al. Lancet Oncol. 2010 Oct;11(10):962-72. doi: 10.1016/S1470-2045(10)70203-5. Epub 2010 Sep 17. Lancet Oncol. 2010. PMID: 20851682 Free PMC article. Clinical Trial.
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. Tran HT, et al. Lancet Oncol. 2012 Aug;13(8):827-37. doi: 10.1016/S1470-2045(12)70241-3. Epub 2012 Jul 2. Lancet Oncol. 2012. PMID: 22759480
81 results